Robert Iannone's Insider Trades & SAST Disclosures
Robert Iannone's most recent trade in Jazz Pharmaceuticals plc was a trade of 2,403 Ordinary Shares done at an average price of $138.4 . Disclosure was reported to the exchange on March 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert Iannone.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Global Head of R&D & CMO | Sale of securities on an exchange or to another person at price $ 138.41 per share. | 10 Mar 2025 | 2,403 | 79,621 (0%) | 0% | 138.4 | 332,605 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Global Head of R&D & CMO | Sale of securities on an exchange or to another person at price $ 138.21 per share. | 05 Mar 2025 | 5,532 | 83,572 (0%) | 0% | 138.2 | 764,578 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Global Head of R&D & CMO | Sale or transfer of securities back to the company at price $ 138.95 per share. | 05 Mar 2025 | 5,239 | 89,104 (0%) | 0% | 138.9 | 727,959 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Global Head of R&D & CMO | Sale of securities on an exchange or to another person at price $ 140.00 per share. | 05 Mar 2025 | 1,548 | 82,024 (0%) | 0% | 140 | 216,720 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, G R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 17,718 | 85,484 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, G R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 8,859 | 94,343 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, G R&D and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 7,506 | 69,947 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, G R&D and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.62 per share. | 17 Jan 2025 | 2,181 | 67,766 (0%) | 0% | 122.6 | 267,434 | Ordinary Shares |
| ITeos Therapeutics Inc | Robert Iannone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 24,200 | 24,200 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Global Head of R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.53 per share. | 05 Mar 2024 | 4,294 | 62,226 (0%) | 0% | 117.5 | 504,674 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Global Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 16,928 | 66,520 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Iannone Robert | EVP, Global Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2024 | 5,970 | 51,322 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Iannone Robert | EVP, Global Head of R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 119.13 per share. | 17 Jan 2024 | 1,730 | 49,592 (0%) | 0% | 119.1 | 206,095 | Ordinary Shares |
| ITeos Therapeutics Inc | Robert Iannone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 22,383 | 22,383 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Global Head of Research a | Sale or transfer of securities back to the company at price $ 129.73 per share. | 05 Jun 2023 | 1,311 | 45,315 (0%) | 0% | 129.7 | 170,076 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Global Head of Research a | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 12,447 | 48,763 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Global Head of Research a | Payment of exercise price or tax liability using portion of securities received from the company at price $ 142.78 per share. | 03 Mar 2023 | 2,274 | 46,489 (0%) | 0% | 142.8 | 324,682 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Global Head of R&D | Sale of securities on an exchange or to another person at price $ 151.54 per share. | 09 Dec 2022 | 1,844 | 36,316 (0%) | 0% | 151.5 | 279,440 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Global Head of R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 149.25 per share. | 06 Jun 2022 | 1,295 | 38,109 (0%) | 0% | 149.3 | 193,279 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Global Head of R&D and Ch | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 11,374 | 40,584 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Global Head of R&D and Ch | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.96 per share. | 03 Mar 2022 | 1,327 | 39,257 (0%) | 0% | 154.0 | 204,305 | Ordinary Shares |
| ITeos Therapeutics Inc | Robert Iannone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 4,560 | 4,560 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 176.47 per share. | 05 Jun 2021 | 1,206 | 29,086 (0%) | 0% | 176.5 | 212,823 | Ordinary Shares |
| ITeos Therapeutics Inc | Robert Iannone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2021 | 33,217 | 0 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP R&D, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 164.75 per share. | 05 Mar 2021 | 741 | 30,145 (0%) | 0% | 164.8 | 122,080 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 8,535 | 30,886 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Robert Iannone | EVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.65 per share. | 05 Jun 2020 | 943 | 22,204 (0%) | 0% | 120.7 | 113,773 | Ordinary Shares |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges